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A B S T R A C T   
Background: Human papillomavirus (HPV) infection is the primary cause of cervical cancer. In 2018, the World 
Health Organization (WHO) Director General announced his commitment to eliminate cervical cancer, with HPV 
vaccination as a priority. However, the costs of setting up a multi-dose HPV vaccination programme remain a 
barrier to its introduction. 
Methods/Design: We are conducting a randomised-controlled trial of reduced dose schedules of HPV vaccine in 
Tanzania to establish whether a single dose produces immune responses that will be effective in preventing 
cervical cancer. 930 girls aged 9–14 years in Mwanza, Tanzania, were randomised to one of 6 arms, comprising 3 
different dose schedules of the 2-valent (Cervarix) and 9-valent (Gardasil-9) HPV vaccines: 3 doses; 2 doses given 
6 months apart; or a single dose. All participants will be followed for 36 months; those in the 1 and 2 dose arms 
will be followed for 60 months. Trial outcomes focus on vaccine immune responses including HPV 16/18-specific 
antibody levels, antibody avidity, and memory B cell responses. Results will be immunobridged to historical 
cohorts of girls and young women in whom efficacy has been demonstrated. 
Discussion: This is the first randomised trial of the single dose HPV vaccine schedule in the target age group. The 
trial will allow us to examine the quality and durability of immune responses of reduced dose schedules in a 
population with high burden of malaria and other infections that may affect vaccine immune responses. Initial 
results (24 months) are expected to be published in early 2021.   
1. Background 
Human papillomavirus (HPV) infection, the primary cause of cervi-
cal cancer, is a major public health problem in sub-Saharan Africa (SSA). 
East Africa has an estimated cervical cancer incidence of around 40/ 
100,000 [1], among the highest in the world. In many countries in SSA, 
screening is absent or limited, and treatment is often sub-optimal. 
In 2018, the Director-General of the World Health Organization 
(WHO) announced his commitment to eliminate cervical cancer [2]. 
Prophylactic HPV vaccines, critical for this elimination goal, are safe and 
highly effective at preventing HPV infection and associated disease. 
Three HPV vaccines are licensed; the bivalent vaccine protects against 
HPV 16/18 (Cervarix®), the 4-valent vaccine against HPV 6/11/16/18 
(Gardasil®), and the 9-valent vaccine against 9 genotypes (HPV 6/11/ 
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16/18/31/33/45/52/58) (Gardasil-9®). 
The vaccine was originally given as a 3-dose schedule. However, a 2- 
dose schedule was approved in 2016 for girls aged <15 years [3]. Of 127 
countries that had included HPV vaccines in their national programmes 
by May 2020, only 22 are low- or middle-income countries (LMIC) [4]. 
The costs of setting up and sustaining a multi-dose HPV vaccine pro-
gramme remain a barrier to its introduction [5,6]. Cost and logistics 
have also limited the implementation of extended age range ‘catch-up’ 
campaigns in existing programmes [7]. New vaccination strategies are 
therefore needed to enable cervical cancer elimination. A 1-dose 
schedule could reduce costs and simplify vaccine delivery, facilitate 
rollout of national programmes and catch-up campaigns, and dramati-
cally reduce the cervical cancer burden globally. 
Data suggest that 1 dose of HPV vaccine may confer sufficient pro-
tection against HPV infection and cervical cancer precursors. Women 
who received 1 or 2 doses of Cervarix® in the Costa Rica Vaccine (CVT) 
and PATRICIA trials (due to non-completion of the 3-dose schedule) had 
similar efficacy against HPV infection over 4 years of follow-up 
compared with those who received 3 doses [8]. Women who received 
fewer than 3 doses in the CVT are being followed long-term, and the 11- 
year efficacy and immunogenicity data support durable protection from 
1 dose [9]. Furthermore, 1 dose provided antibody levels well above 
those found following natural infection. A trial of Gardasil® in India 
found that participants who received only 1 dose had similar incident 
and persistent HPV infections over 7 years as those receiving 3 doses 
[10]. Whilst these results challenge the established belief that protein- 
based subunit vaccines require a prime-boost regimen, they provide 
insufficient evidence to change vaccine recommendations because of 
their non-randomised design and post-hoc character. 
The 2-dose schedule in girls aged <15 years was approved based on 
immunogenicity studies in high and upper middle-income countries. 
However, it is conceivable that the efficacy of reduced-dose schedules 
could be affected by intercurrent infections such as helminths or malaria 
[11]. We are conducting a randomised-controlled trial of reduced dose 
schedules of 2 HPV vaccines in Tanzania, to establish whether 1 dose 
produces immune responses that are likely to be effective in preventing 
cervical cancer in SSA. This is the first randomised trial of the single dose 
schedule in 9 to 14 year-old girls, the primary target group for this 
vaccine globally. 
1.1. Trial objectives and outcomes 
The overall objective of this trial is to determine whether a single 
dose of the bivalent vaccine (Cervarix®) or 9-valent vaccine (Gardasil- 
9®) produces immune responses that are non-inferior to those following 
2 and 3 doses when given to HIV negative girls aged 9 to 14 years in a 
malaria-endemic region of Tanzania, and whether these immune re-
sponses are affected by malaria infection. We will also compare immune 
responses after 1 dose in young girls in Tanzania with those in historical 
cohorts of girls and young women who received 1, 2 or 3 doses of HPV 
vaccine, in whom efficacy has been demonstrated. 
The trial outcomes focus on vaccine immune responses as measured 
by: (1) the proportion of participants seroconverting to HPV types 16/ 
18; (2) geometric mean titre (GMT) of HPV 16/18-specific antibodies; 
(3) HPV 16/18-specific antibody avidity; and (4) HPV 16/18-specific 
memory B cell responses. 
The trial has two co-primary objectives: 1) to demonstrate non- 
inferiority of HPV 16/18-specific seropositivity following 1 dose of 
HPV vaccine compared with 2 or 3 doses of the same vaccine at month 
(M)24; and 2) to demonstrate non-inferiority of antibody GMT at M24, 
when comparing the 1 dose regimen of either vaccine with historical 
cohorts of women aged 10–25 years who received 1 dose, in whom ef-
ficacy has been demonstrated. Secondary immunogenicity objectives 
include evaluation of HPV 16/18 antibody GMT and seropositivity at 
other timepoints, evaluation of antibody avidity and memory B cell re-
sponses, comparison of immune responses after 2 versus 3 doses, 
comparisons of the same dose regimen between vaccine types, and 
comparisons between girls who had malaria at the time of vaccination 
and those who did not. The primary focus is on HPV16/18; however, the 
antibody response to the other HPV genotypes covered by the 9-valent 
vaccine will also be explored. Other secondary objectives are evalu-
ating cost effectiveness and acceptability of the 1 dose schedule. 
Girls in the 1- and 2-dose arms will be invited to enrol in a trial 
extension, to examine the durability and stability of immune responses 
up to 60 months. The primary objective of the trial extension is to 
demonstrate non-inferiority of HPV 16/18-specific seropositivity when 
comparing 1 dose with 2 doses of the same vaccine at M60. 
2. Methods 
2.1. Study design and population 
This is an open-label, individually-randomised controlled trial of two 
HPV vaccines being conducted at the Mwanza Intervention Trials Unit 
(MITU), in the lake zone region of north-western Tanzania [Dose 
Reduction Immunobridging and Safety Study of two HPV vaccines in 
Tanzanian girls (DoRIS); NCT02834637]. 
The trial has 6 arms comprising 3 different dose schedules of the 
bivalent or 9-valent HPV vaccines: the originally recommended 3 dose 
schedule; 2 doses given 6 months apart; or a single dose (Table 1). All 
girls will be followed for 36 months; those who consent to the extension 
will be followed for 60 months. 
The trial has enrolled 930 HIV-negative schoolgirls living in 
Mwanza. Enrolment began in March 2017 and ended in January 2018; 
follow-up is expected to end in May/June 2021 for the main trial (owing 
to SARS-CoV-2 outbreak and postponement of some M36 visits) or 
January/February 2023 for the extension. Girls were eligible for inclu-
sion in the main trial if aged 9–14 years, planning to be resident in 
Mwanza for 36 months and willing and able to give informed assent, 
with informed consent from parent/guardian. Girls were excluded if 
they had previously received any dose of HPV vaccination, had a past 
history of cervical lesions or genital warts, had received treatment for 
positive cervical screening, were pregnant at screening, were immuno-
compromised, including HIV infection, or were unwell on the basis of 
medical history, clinical examination or laboratory tests. At the M36 
visit, all girls in the 1 and 2 dose arms will be invited to participate in the 
trial extension. 
2.2. Randomisation 
Eligible participants were randomised to one of the 6 study arms in a 
1:1:1:1:1:1 allocation, using random permuted block sizes of 12, 18 and 
24. The randomisation list was computer-generated by an independent 
statistician, with the treatment allocation order defined by the blocks 
and sequence within blocks. Trial participant identification numbers 
were generated within the computer program, and sequentially assigned 
in the order of the treatment allocations. 
Table 1 
Design of the trial Dose Reduction Immunobridging and Safety Study of two HPV 
vaccines in Tanzanian girls (DoRIS).  
Arm 2-valent HPV vaccine 
(Cervarix®) 















A B C D E F 
Number of 
girls 
155 155 155 155 155 155 930  
a Given at Day(D)0, Month(M) 1 and M6. 
b Given at D0 and M6. 
c Given at D0, M2 and M6. 
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A set of sequentially-numbered opaque sealed envelopes, each con-
taining a unique participant identification number with its allocation, 
were prepared by the independent statistician in advance of the enrol-
ment visit and sent to the research clinic. At the enrolment visit, after 
eligibility was confirmed, the study clinician responsible for enrolment 
opened the next available envelope in the numbered sequence in order 
to find the participant’s identification number and assigned allocation. 
The identification number and allocation were recorded on the partici-
pant’s case report form (CRF). 
2.3. Sample size 
With the 2- and 3-dose schedules of either HPV vaccine, it is esti-
mated that 99% will be seropositive for HPV16/18 at M24 [12]. With 
155 in each HPV-dose schedule arm, assuming <5% have HPV 16/18 
antibodies or are HPV 16/18 DNA positive at enrolment (based on our 
previous studies in Tanzania), [13–15] and a projected 20% loss to 
follow up (LTFU) over 36 months, we expect to have around 130 girls in 
each arm at the M24 visit for the primary outcome analyses, 120 girls at 
M36, and 100 at M60. 
If the true proportion seroconverting is the same in each arm, with 
130 girls per arm, we will have >90% power to conclude that sero-
positivity with the reduced dose schedule is not decreased by more than 
5.0%, using a one-sided non-inferiority test at the 2.5% level (Table 2). 
This non-inferiority margin is the same that was used in the trials leading 
to licensure of the 2-dose regimen in girls aged <15 years [16]. If the 
true GMT ratio (reduced dose arm: comparison cohort) between groups 
is 1.0, with 130 girls in each group, we will have >90% power to 
conclude that the reduced dose schedule does not decrease anti-HPV 16/ 
18 GMT by more than 50%, corresponding with a reduction of 0.30 in 
log titre. The non-inferiority margin was based on pre-established 
standards from the US Food and Drug Administration (FDA) that have 
been used in other HPV vaccine bridging trials [16,17]. We have 
assumed an SD of 0.50–0.60 log10 anti-HPV titre [12], and used a one- 
sided non-inferiority test at the 2.5% level. 
2.4. Study interventions 
Both vaccines used in this trial are licensed by the US Food and Drug 
Administration (FDA). The bivalent HPV vaccine (Cervarix®), produced 
by GSK Biologicals, contains HPV 16/18 virus-like-particles (VLP). The 9 
valent vaccine is produced by Merck (Gardasil-9®) and contains HPV 6, 
11, 16, 18, 31, 33, 45, 52 and 58 VLPs. The bivalent vaccine has an 
adjuvant consisting of monophosphoryl lipid A (MPL) and aluminium 
hydroxide. MPL is a detoxified bacterial lipopolysaccharide which is a 
TLR-4 agonist which causes activation of both innate and adaptive im-
mune responses [18] The 9-valent vaccine uses a more traditional 
aluminium adjuvant (aluminium hydroxyl-phosphate sulphate), similar 
to that of the 4-valent vaccine, but in a higher dose. Antibody levels 
produced by the bivalent vaccine are significantly higher than those 
produced by the 4-valent vaccine both for HPV 16 and 18 and for cross- 
protected types [19]. 
3. Study procedures 
3.1. Preparatory activities 
Girls were enrolled from 36 primary and 18 secondary government 
day schools in Ilemela municipality, Mwanza city. In the month before 
the screening visit, study mobilisers held meetings with community and 
religious leaders and heads of schools to explain the trial. Parents/ 
guardians of potentially eligible girls attending the selected schools were 
invited to a meeting at the school where the trial and informed consent 
and assent procedures were explained. Parents/guardians were then 
approached individually and invited to attend the research clinic with 
their daughters for screening. 
3.2. Screening and enrolment 
A summary of the study procedures is shown in Table 3. At the 
screening visit, girls had the trial aims, eligibility criteria and procedures 
explained. Parents/guardians and girls were asked for their informed 
written/witnessed consent and assent, respectively. All girls aged ≥12 
years were required to pass a Test of Understanding (TOU) in order to be 
eligible for enrolment; for younger girls, the parent/guardian was 
required to pass the TOU. Parents/guardians and girls were allowed to 
retake the test twice if they failed to reach the pass score of >90%. If the 
TOU was passed, girls were screened for eligibility, including a medical 
history with a physical examination if indicated, HIV counselling and 
testing and a urine test was performed for pregnancy. Girls who were 
HIV positive were not eligible for enrolment, but were encouraged to 
share the test result with their parent/guardian, and were referred for 
CD4 count assessment and HIV care. Girls who were found to be preg-
nant at the screening or enrolment visit were considered to be a 
screening failure and were also ineligible. 
The enrolment visit was within 30 days after screening. A brief 
interview was conducted, another urine pregnancy test was done, and 
eligibility criteria were re-confirmed by the study clinician. If deemed 
eligible, the participant was enrolled and randomised to receive the first 
dose of vaccine. Girls who were ineligible because of medical history 
and/or physical examination were referred to a doctor for appropriate 
medical management according to local treatment guidelines. 
Digital fingerprints were taken in order to confirm a participant’s 
identity throughout the study. The fingerprint record was stored elec-
tronically and linked only to the participant identification number, not 
to the participant’s name or any personal identifiers. Each participant 
was also given a study photo identification (ID) card. Before the first 
dose was given, a venous blood sample was collected for immunoge-
nicity assays, HSV-2 serology, and a dried blood spot (DBS) for storage 
for malaria testing by polymerase chain reaction (PCR). Two nurse- 
assisted, self-administered vaginal swabs were collected for HPV DNA 
testing and HPV genotyping. This method of sample collection has been 
successfully used in other studies of HPV in girls in Mwanza [14,15]. 
3.3. Vaccination phase 
Vaccination was conducted at enrolment (Day(D) 0; all arms), M1 or 
M2 (3-dose arms; Cervarix and Gardasil-9, respectively) and M6 (2- and 
3-dose arms). A short medical history and repeat urine pregnancy test 
was done at each vaccination visit prior to vaccination. Vaccination was 
postponed if the girl was deemed to have an acute illness that precluded 
vaccination. Girls who were pregnant did not receive any further doses 
of vaccine but continued with the study follow-up visits. 
Vaccines were administered via intramuscular injection into the 
Table 2 
Non-inferiority margins that can be demonstrated with 90% power, for different 
assumptions of number of subjects evaluable in each arm.  
Outcome Number 
evaluablea 









130 99% 4.0% 90% 
100 99% 4.6% 90% 
85 99% 5.0% 90% 
HPV 16/18 antibody 
GMT ratioc 
130 1.0 0.57 90% 
100 1.0 0.53 90% 
85 1.0 0.50 90%  
a Evaluable subjects are those attending at M24, M36 or M60 who are HPV 
16/18 DNA and antibody negative at enrolment. 
b Non-inferiority defined as lower bound for 95% 2-sided CI for difference in 
proportions/ratio of GMT being above this margin. 
c Assuming an SD of 0.60 log10 anti-HPV titre. 
K.J. Baisley et al.                                                                                                                                                                                                                               
Contemporary Clinical Trials 101 (2021) 106266
4
deltoid region of the upper arm. After vaccination, participants were 
observed for at least 30 min, with appropriate medical treatment and 
equipment available in case of any anaphylactic reaction. The study staff 
monitored the participant’s vital signs and looked for injection site re-
actions and other adverse events, which were recorded on the CRF. At 
each vaccination visit, a blood sample was collected for a DBS, which 
was stored for malaria PCR testing. 
Participants attended the clinic one month after each vaccination 
visit for questioning about adverse events in the 30 days after vaccina-
tion, and for blood sampling for immunogenicity outcomes. The win-
dows for vaccination and blood sampling are in Table 4. 
3.4. Follow-up 
All participants were asked to attend the clinic at M6 and M7 to 
collect a blood sample for a DBS for malaria PCR (M6) and for vaccine 
immunogenicity assays (M7). Scheduled follow-up visits are at M12, 
M24 and M36, and a blood sample is collected for immunogenicity. 
Participants in the trial extension will also be followed up at M48 and 
M60, and an immunogenicity blood sample will be collected at M60. 
At M18 and M30 (and M42 and M54 in the trial extension), partic-
ipants are visited at home or at school to ensure that they are still living 
in Mwanza and to update contact details if needed. Participants are 
questioned about AEs at all study visits. In addition, to help ensure a 
high rate of retention between visits, participants are sent an SMS 
reminder or telephoned about the trial every 3 months. 
In April 2020, the trial was temporarily suspended owing to the 
SARS-CoV-2 outbreak; a protocol amendment was submitted to increase 
the window for the M36 blood sample (Table 4). The Tanzanian Na-
tional Health Research Ethics Sub-Committee (NatHREC) gave permis-
sion for studies to resume activities as per protocol on 18 May 2020 
provided that training is done in small groups and COVID-19 preven-
tative measures, such as mask-wearing, physical distancing and hand 
hygiene, are implemented for research activities. The trial team resumed 
month 36 visits on 3 August 2020. 
3.5. Laboratory assays 
Whole blood samples of up to 20 mL (depending on girl’s weight) are 
collected for immunological assays, in order to provide 10 mL of serum 
and 10 mL for peripheral blood mononuclear cells (PBMC). All samples 
are processed and stored initially at the laboratory at the National 
Institute of Medical Research (NIMR) in Mwanza, before being shipped 
to the relevant laboratory for analysis. HPV 16/18 antibodies will be 
measured by a qualified anti-VLP ELISA assay at the Frederick National 
Laboratory for Cancer Research HPV Immunology Laboratory in Mary-
land, USA [20]. The primary analyses will be based on antibody GMT as 
measured in this VLP ELISA. The HPV 16/18-specific antibody avidity 
index (AI) will be determined in the ELISA by the ratio of antibody 
concentrations in serum samples treated or not treated with Guanidine- 
HCl [21]. HPV 16/18-specific memory B cell responses will be measured 
in PBMCs by a B cell ELISPOT assay at the Centre for Immunology and 
Table 3 
Summary of study procedures.  
Study procedure Screen < 30 
d 
D0 M1 M2 M3 M6 M7 M12 M18 M24 M30 M36 M42g M48g M54g M60g 
Informed consent/assent X                
Informed consent/assent for trial 
extension            
Xg     
Demographics & tracing info X           Xg     
Medical historya X                
Test of Understanding X                
Blood sampling for HIV X                
Pregnancy test X X Xb Xb  Xb           
Check LMP & pregnancy test if 
indicated   
Xc Xc X Xc X X  X  X  X  X 
Eligibility check X X               
Clinic visit X X X Xd Xd X X X  X  X  X  X 
Home, clinic or school visit         X  X  X  X  
Blood sampling for immunogenicity  X X    X X  X  X    X 
Vaginal swabs for HPV genotyping  X               
Blood sampling for malaria  X Xb Xb  X           
Blood sampling for HSV-2  X     Xe Xe  Xe  Xe    X 
Review of medical historya  X Xb Xb  Xb           
Check deferral criteria and 
contraindications  
X Xb Xb  Xb           
Vaccine administration  X Xb Xb  Xb           
Recording of AEs in 30 days post 
vaccination   
X Xf Xf  Xf          
Recording of unsolicited AEs/SAE  X X X X X X X X X X X X X X X  
Timing of laboratory assays 
HPV antibody ELISA  X X    X X  X  X    X 
HPV antibody avidity        X  X  X     
Memory B cells  X X    X X  X  X     
PSV Luminex assay  X X    X X  X  X    X 
Malaria  X Xb Xb  X           
HSV-2  X     Xe Xe  Xe  Xe    X 
HIV X                 
a Examination if warranted. 
b Only for those randomised to vaccine at that visit. 
c For those not randomised to receive vaccine at that visit. 
d M2 visit attended by 3 dose arms only; M3 visit attended by 3 dose Gardasil-9 arm only. 
e Storage of serum sample for HSV-2 serology at last visit attended. 
f Questions about AEs that occurred in the 30 days since the last dose, only for those participants who received vaccine at the previous visit. 
g Extension activities will be conducted for girls in 1 and 2 dose arms only. 
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Infection, York, UK; detectable HPV type-specific memory B-cells will be 
defined as >1 antigen-specific memory B cell/million memory B cells 
[22]. Serum HPV antibody titres to the HPV genotypes in the 9-valent 
vaccine are being measured by a pseudovirion (PsV)-based antibody 
Luminex assay at the Karolinska Institute, Sweden; the assay has shown 
high correlations with VLP-ELISA and neutralisation assays, and with 
natural infection [23–25]. HPV DNA genotyping at D0 was done using 
the Anyplex HPV28 (Seegene, South Korea) detection assay at the 
Catalan Institute of Oncology, Barcelona. 
3.6. Data management 
All completed CRFs and laboratory forms are submitted to the MITU 
data section. Data are double-entered into a study-specific database by 
trained data entry staff, using the OpenClinica open source software. 
Data checks and data cleaning are done by trained data managers at 
MITU under the supervision of a senior data manager. Submitted CRFs 
and forms are stored securely in locked filing cabinets in the MITU data 
department. At the conclusion of the study, the database will be 
archived in accordance with internal procedures. 
3.7. Statistical analysis 
In non-inferiority trials, intention-to-treat (ITT) analyses may in-
crease the risk of falsely claiming non-inferiority, since these analyses 
often lead to smaller observed effects than if all participants had adhered 
to the protocol [26]. Therefore, for the non-inferiority objectives, we 
will conduct the primary analyses in the per-protocol (PP) population, 
and repeat all analyses in the intention-to-treat (ITT) population as a 
sensitivity analysis. The PP population will be girls who receive the 
allocated doses of vaccine within the specified windows in Table 4 and 
are HPV antibody and DNA negative at enrolment for the specific ge-
notype under analysis. 
Seropositivity for a particular HPV vaccine genotype will be defined 
as antibody level above the assay cut-off; the cut-off value will be 
defined by the laboratory before the analysis begins. We will measure 
the proportion of girls in each arm who are seropositive for each HPV 
vaccine genotype, and calculate the difference (reduced dose group 
minus comparison group) between arms. We will estimate the 95% CI 
for the difference using the Farrington and Manning approach [27]. 
Non-inferiority will be concluded if the lower 95% CI for the difference 
is above − 5%. 
The ratio of HPV genotype-specific GMTs will be obtained from an 
analysis of variance (ANOVA) of log10 antibody titres as the response 
variable. Separate analyses will be done for each vaccine genotype and 
time point. The ANOVA model will include trial group as a fixed effect. 
For each vaccine type (Cervarix and Gardasil-9), a contrast will be 
derived from the ANOVA model comparing the mean of log10 titre in the 
reduced dose group with that in the comparison group, using the re-
sidual error from the ANOVA. The GMT ratio and its 95% CI will be 
derived from back-transformation of the mean and 95% CI from this 
contrast. Non-inferiority will be concluded if the lower bound for the 
95% two-sided CI for the GMT ratio (reduced dose group divided by 
comparison group) is above 0.50. 
The primary analyses will exclude girls with missing immunoge-
nicity results (complete case), but a sensitivity analysis using multiple 
imputation of missing data may be done at month 36, and/or month 60. 
For the primary objectives, non-inferiority for each vaccine type will 
be concluded if the lower limit for the 95% CI for the seroconversion 
difference between 1 dose vs 2 doses, and between 1 dose vs 3 doses, is 
above − 5% for both HPV16 and HPV18. For comparisons with historical 
cohorts, non-inferiority for each vaccine type will be concluded if the 
lower limit of the 95% CI is for the GMT ratio (1D/historical cohort) is 
above 0.50 for both HPV16 and HPV18. For the secondary objectives, a 
hierarchy of testing for the non-inferiority objectives will be pre- 
specified in a statistical analysis plan. 
A subgroup analysis will be done to compare immune responses 
between girls who were positive and negative for malaria at vaccination. 
Since malaria is measured at different timepoints relative to enrolment 
depending on arm, these will primarily focus on comparisons within 
arm, or between the same dose regimens (e.g. 1 dose of bivalent vs. 1 
dose of 9-valent). 
Full details of the statistical methods will be covered in a formal 
Statistical Analysis Plan that will incorporate a formal plan for the 
Table 4 
Window periods for vaccination and follow-up visits.  
Procedure Armsa Visit Recommended date Minimum date Maximum date 
Vaccination visits 
Dose 1 All D0 Date of first vaccination (DFV) N/A N/A 
Dose 2 A M1 DFV +30 days DFV +30 days DFV +60 days 
Dose 2 D M2 DFV +60 days DFV +30 days DFV +90 days 
Dose 2 B and E M6 DFV +181 days DFV +181 days DFV +271 daysb 
Dose 3 A and D M6 DFV +181 days DFV +181 days DFV +271 daysb  
Follow-up visits 
D0 blood sample All D0 DFV N/A N/A 
M1 blood sample and AE 
recordingc 
All M1 DFV +30 days DFV +30 days DFV +60 days 
M2 AE recordingc A M2 Date of second vaccination +30 
days 
Date of second vaccination +30 
days 
Date of second vaccination +60 
days 
M2 blood sample for malaria D M2 Date of second vaccination N/A N/A 
M3 AE recordingc D M3 Date of second vaccination +30 
days 
Date of second vaccination +30 
days 
Date of second vaccination +60 
days 
M6 blood sample for malaria A, B, D and E M6 Date of last vaccination Date of last vaccination Date of last vaccination 
M6 blood sample for malaria C and F M6 DFV +181 days DFV +181 days DFV +211 days 
M7 blood sample A, B, D and E M7 Date of last vaccination +30 days Date of last vaccination +30 days Date of last vaccination +60 days 
M7 blood sample C and F M7 DFV +211 days DFV +211 days DFV +241 days 
M12 blood sample All M12 DFV +361 days DFV +361 days DFV +391 days 
M24 blood sample All M24 DFV +723 days DFV +723 days DFV +753 days 
M36 blood sample All M36 DFV +1085 days DFV +1055 days DFV +1265 daysd 
M60 blood sample B, C, E, F M60 DFV +1809 days DFV +1779 days DFV +1839 days  
a Arms A, B and C receive 3 doses, 2 doses and 1 doses of Cervarix®, respectively. Arms D, E and F receive 3 doses, 2 doses and 1 doses of Gardasil-9®, respectively. 
b For ethical reasons, girls may receive the last dose up to 360 days after DFV; however, they may be excluded from the immunogenicity analysis. 
c Solicited signs and symptoms in the 30 days after each vaccine dose. 
d Window extended because of SARS-CoV-2 outbreak and postponement of some M36 visits. 
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immunobridging analyses. For the secondary objectives, a hierarchy of 
testing for the non-inferiority objectives will be pre-specified. The 
analysis plan will also include pre-specified criteria for non-inferiority, 
plans for adjustment for multiplicity, and other statistical consider-
ations for non-inferiority trials with immunogenicity endpoints, as 
outlined by Liu et al. [28] The final analysis plan will be approved by the 
Independent Data Safety and Monitoring Board (IDSMB), the Trial 
Steering Committee (TSC), and the Principal Investigators before the 
randomisation code is released and the data are analysed. 
3.8. Immunobridging 
We will bridge our results to historical cohorts of girls and young 
women aged 10–25 years who received 1, 2 or 3 doses, in whom efficacy 
has been demonstrated. These include the previous trial of the bivalent 
vaccine in Costa Rica, the CVT (NCT00128661), which vaccinated 
young women aged 18–25 years [29], and the International Agency for 
Research on Cancer (IARC) trial of the 4-valent vaccine in India 
(NCT00923702), which vaccinated girls and young women aged 10–18 
years [10]. In addition, we will bridge our immunogenicity results to 
those of the National Cancer Institute’s (NCI) large randomised 
controlled trial to evaluate the efficacy of the bivalent and 9-valent 
vaccines given as 1 or 2 doses to girls aged 12–16 years in Costa Rica 
(the ESCUDDO trial; NCT03180034) and with which our trial protocol 
has been harmonised. Bridging with a recently started efficacy trial in 
Kenya in young women aged 15–20 (KEN-SHE; NCT03675256) is also 
planned. Results from these trials are expected in 2023 (KEN-SHE) and 
2025 (ESCUDDO). 
3.9. Ethics and oversight 
The trial protocol was approved by the ethical committee of the 
Medical Research Coordinating Committee, Tanzania (NIMR/HQ/R.8A/ 
Vol.IX/2236), and the London School of Hygiene and Tropical Medicine 
(11568). Written informed consent is obtained from parents/guardians, 
with written assent from participants. A TSC and IDSMB were estab-
lished to monitor trial progress. A community advisory board (CAB) 
comprising parents, teachers and other community members was 
established to advise the research team. Trial monitoring is being done 
by independent trial monitors from Kenya Medical Research Institute 
(KEMRI) in Kenya. 
4. Discussion 
This is the first randomised trial of the single dose schedule of HPV 
vaccine in 9–14 year old girls, the primary target group for HPV vaccine 
globally, and the first randomised trial of HPV vaccine dose reduction in 
SSA. Final results from the main trial are expected in early 2022, with 
interim results submitted for publication in early 2021. Other trials 
evaluating single dose protection have recently begun in Costa Rica, The 
Gambia and Kenya, with results available at the end of 2022 or later. 
These trials are all complementary, examining single-dose HPV vacci-
nation for girls, adolescents, and young women aged 4–20 years, and 
address different scientific and programmatic questions. 
In addition to comparisons between trial arms, our trial will compare 
vaccine-induced HPV-specific immune responses in young girls in 
Tanzania with those in historical cohorts of girls and young women who 
received 1, 2 or 3 doses of HPV vaccine, in whom efficacy has been 
demonstrated. We will also bridge our results with those from ongoing 
efficacy trials in Costa Rica and Kenya; our trial protocol is also 
harmonised with that of the ongoing trial in Costa Rica to maximise 
comparability between the 2 trials. Since it is difficult to evaluate HPV 
vaccine efficacy in young girls because of the time needed to accrue 
endpoints, immunobridging studies are used to infer protection when 
efficacy has been demonstrated in another population [30]. 
The true immunological correlates of protection for HPV vaccines 
have not yet been established. Age is a key determinant of antibody 
responses following HPV vaccination, with young girls having signifi-
cantly higher antibody GMTs than young women [12,17]. Although the 
2 dose regimen in girls aged <15 years has been approved based on 
vaccine-specific antibody levels, there is increasing recognition that 
vaccine efficacy depends on both quantity and quality of antibodies 
induced by the vaccine. Quality, measured by avidity of antibodies for 
the antigen, depends on priming of B cells which produce antibodies 
with different affinities for antigen. It is not known whether antibody 
affinity, memory B cell responses and durability of protection with fewer 
doses of HPV vaccine may be affected by intercurrent infections such as 
malaria or helminths. Our previous trial of 3 doses of the bivalent HPV 
vaccine in Tanzania found that girls who had malaria at the time of 
vaccination had significantly higher HPV 16/18 antibody levels one 
month after the last dose compared with girls who did not have malaria 
[31]. Malaria induces polyclonal antibodies which may enhance 
vaccine-induced anti-VLP antibodies, but the quality of these antibodies 
related to vaccine-induced protection is not known [32]. Ours, and the 
other ongoing one-dose trials, will help provide definitive answers to 
questions about non-inferiority of 1 dose of HPV vaccine compared with 
2 doses, in terms of immunogenicity and HPV infection, and the feasi-
bility of dose reduction. 
Following the call from the WHO Director General in 2018, a Global 
Strategy for elimination of cervical cancer as a public health problem 
was drafted [33]. This calls for a comprehensive approach that includes 
prevention, screening and treatment, with a proposed global target that 
90% of girls aged ≤15 years have been vaccinated for HPV by 2030. In a 
meeting of the WHO Strategic Advisory Group of Experts (SAGE) in 
October 2018, HPV vaccination was declared to be the most critical 
intervention for eliminating cervical cancer [34]. More recently, the 
World Medical Association announced its commitment to cervical can-
cer elimination, emphasising the need to improve HPV vaccination 
coverage [35]. However, the commitment to eliminate cervical cancer 
will be difficult to achieve without novel vaccination strategies to reduce 
HPV infection. A single dose schedule could help achieve this goal by 
reducing the cost and complexity of delivery. 
In 2019, estimated global coverage among girls in the target range 
for vaccination (9–14 years) was 40%, and only 8–9% of 10-20-year-old 
girls have been vaccinated [36]. An estimated 30% of girls aged 9–14 
years globally live in countries that have introduced the HPV vaccine, 
which means that many girls in the target age range for the vaccine are 
likely to remain unvaccinated [37]. The Tanzanian national HPV 
vaccination programme was rolled out in 2018, and is delivering 2 doses 
of the 4-valent vaccine (Gardasil®) to girls aged 14 years. However, 
coverage in 2019 was only 49% [unpublished data from the Tanzanian 
Ministry of Health provided to MITU/NIMR]. Furthermore, HPV vaccine 
supply has been constrained since 2018, which has affected HPV 
vaccination programmes worldwide, and supply is predicted to remain 
constrained for the next 3–5 years [37]. In their 2018 meeting, SAGE 
called for a comprehensive evaluation of options for the best use and 
allocation of the limited vaccine supply [35]. Given the large number of 
countries that have yet to adopt an HPV vaccination program, the lower 
cost and greater flexibility of a 1 dose HPV vaccination schedule has the 
potential to increase HPV vaccine introductions globally. The 1 dose 
schedule would also facilitate the introduction of the HPV-FASTER 
scheme, which proposes to combine HPV vaccination in women aged 
up to 30 years with at least one HPV-screening test, as a means to 
accelerate cervical cancer elimination [7]. 
Strengths of our trial are the comparison of two vaccine types, and 3 
dosing schedules, allowing us to compare between/within vaccine types 
and dose schedules. Our outcomes focus on a full range of immune re-
sponses, including anti-VLP antibody levels, neutralising antibodies, 
antibody avidity, and memory B cell responses and the impact of malaria 
on these responses. There are no data on HPV vaccine antibody avidity 
or B cell memory from SSA, and no data on these functional aspects of 
the immune response for the 9-valent vaccine, so this will be the first 
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trial to examine and compare these. We are also including a component 
to evaluate cost effectiveness and acceptability of the 1 dose schedule. 
A limitation of our trial is that we are not collecting efficacy data 
because of the long duration of follow-up and large sample size that 
would be required, and because this is being done in the trial in Costa 
Rica with which we are harmonised (the ESCUDDO trial; 
NCT03180034). We are immunobridging to that trial and other earlier 
large efficacy studies in a variety of populations and settings, which will 
allow us to infer reproducibility of efficacy across different regions. 
In summary, our trial will contribute robust evidence of the effect of 
the 1 dose schedule on a range of immune responses among young girls 
in SSA, and whether these may provide sufficient protection against HPV 
infection. The combined evidence from this and other ongoing 1 dose 
trials will provide critical information for policy-makers on the efficacy 
of this HPV vaccination strategy, which could alleviate vaccine supply 
constraints and expand access to the vaccine in the countries that need it 
most. 
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